adamantane has been researched along with piperidines in 107 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (3.74) | 18.7374 |
| 1990's | 5 (4.67) | 18.2507 |
| 2000's | 19 (17.76) | 29.6817 |
| 2010's | 65 (60.75) | 24.3611 |
| 2020's | 14 (13.08) | 2.80 |
| Authors | Studies |
|---|---|
| Day, CE; Phillips, WA; Schurr, PE | 1 |
| Day, CE; Heyd, WE; Lednicer, D; Schurr, PE | 1 |
| Day, CE; Schurr, PE | 1 |
| Barnes, PJ; Mak, JC | 1 |
| Bloomquist, W; Calligaro, DA; Cohen, I; Cohen, ML; Schaus, JM; Susemichel, AD; Thompson, DC | 1 |
| Bivalacqua, TJ; Champion, HC; Czapla, MA; Ilgenfritz, C; Kadowitz, PJ; Santiago, JA | 1 |
| Betancur, C; Burgos, A; Canton, M; Gully, D; Labeeuw, B; Pélaprat, D; Rostène, W | 1 |
| Bédard, PJ; Di Paolo, T; Falardeau, P; Goulet, M; Grondin, R; Morissette, M; Rostène, W | 1 |
| Matthews, RT | 1 |
| Andrén, PE; Ekesbo, A; Gunne, LM; Sonesson, C; Tedroff, J | 1 |
| Trudeau, LE | 1 |
| Anderson, JE; Foscolos, GB; Fytas, G; Kolocouris, A; Kolocouris, N; Outeiriño, JG | 1 |
| Gebicka, L; Kochman, A; Metodiewa, D; Skolimowski, J | 1 |
| Iba, Y; Kamei, C; Kayasuga, R; Nakamura, Y; Sugimoto, Y | 1 |
| DiPatrizio, NV; Järbe, TU; Lu, D; Makriyannis, A | 1 |
| Brown, CM; Lu, D; Makriyannis, A; McLaughlin, PJ; Salamone, JD; Thakur, G; Winston, KM | 1 |
| Lebovitz, H | 1 |
| De Clercq, E; Foscolos, GB; Fytas, G; Kolocouris, A; Kolocouris, N; Neyts, J; Padalko, E; Setaki, D; Stamatiou, G; Tataridis, D | 1 |
| Kopjar, N; Petek, MJ; Radić, B; Vrdoljak, AL; Zeljezić, D | 1 |
| Kelly, JW; Sawkar, AR; Whalen, LJ; Wong, CH; Yu, Z | 1 |
| Augustyns, K; Brandt, I; Chen, X; Cheng, JD; De Meester, I; Dubois, V; Lambeir, AM; Maes, MB; Scharpé, S; Van der Veken, P | 1 |
| Klein, HH; Meier, JJ; Schmidt, WE | 1 |
| Bondarenko, OY; Bugas, RV; Kochubey, SM; Melnyk, AK; Shevchenko, VV; Tanchuk, VY; Vovk, AI | 1 |
| Brown, C; Fan, P; Makriyannis, A; McLaughlin, PJ; Olszewska, T; Olzewska, T; Pang, Y; Parker, LA; Peng, Y; Salamone, JD; Sink, KS; Thakur, GA; Vemuri, VK; Wood, JA | 1 |
| Gwaltney, SL | 1 |
| De Clercq, E; Kolocouris, N; Naesens, L; Zoidis, G | 1 |
| Argyrakopoulou, G; Doupis, J | 1 |
| Kawahara, H; Mitchell, VA; Vaughan, CW | 1 |
| Mrsić, G; Petek, MJ; Vrdoljak, AL | 1 |
| Cefalu, WT | 1 |
| Kuritzky, L | 1 |
| Scheen, AJ | 2 |
| Gerich, J | 1 |
| Hammock, BD; Inceoglu, B; Jones, PD; Liu, JY; Morisseau, C; Rose, TE; Sanborn, JR | 1 |
| Boudes, P; Viereck, C | 1 |
| Bourdel-Marchasson, I; Dejager, S; Schweizer, A | 1 |
| Barbosa, F; Bogatcheva, E; Chen, P; de los Santos, G; Einck, L; Hanrahan, C; Nacy, C; Nikonenko, B; Protopopova, M; Reddy, V | 1 |
| Barbee, T; Correa, I; Fredrickson, J; Gibbs, JP; Gibbs, MA; Lin, SL; Smith, B | 1 |
| Edwards, KL; Irons, BK; Stapleton, MR; Weis, JM | 1 |
| Ishikawa, M; Yamada, Y | 1 |
| Bajaj, S; Bergman, J; Makriyannis, A; Nikas, SP; Paronis, CA; Thakur, GA; Vemuri, VK | 1 |
| Dimas, K; Eleutheriades, A; Foscolos, GB; Georgakopoulou, S; Khan, H; Kourafalos, VN; Mantelas, A; Mirjolet, JF; Moutsos, VI; Papanastasiou, I; Pondiki, S; Prassa, M; Riganas, S; Serin, G; Theodoropoulou, M; Tsotinis, A; Vamvakides, A; Zaniou, A | 1 |
| Favarato, D; Garzillo, CL; Girardi, P; Hueb, W; Kalil Filho, R; Lima, EG; Rahmi, RM; Ramires, JA; Rezende, PC; Strunz, CM; Takiuti, M; Uchida, AH | 1 |
| Itoh, H; Saisho, Y | 1 |
| Bakris, GL; Flynn, C | 1 |
| Akahoshi, F; Ishii, S; Kadowaki, T; Kishida, H; Miyaguchi, I; Nabeno, M; Tanaka, Y | 1 |
| Charbonnel, B; Dejager, S; Schweizer, A | 1 |
| Abushik, PA; Antonov, SM; Eaton, MJ; Sibarov, DA; Skatchkov, SN | 1 |
| Cohen, D | 1 |
| Lim, GB | 1 |
| Greenhill, C | 1 |
| Mitka, M | 1 |
| Goto, C; Mizui, T; Ohta, H; Tachi, T; Teramachi, H; Toyoshima, M; Tsuchiya, T | 1 |
| Greco, N; Katz, DA; Lenz, RA; Liu, W; Marek, GJ; Meier, A; Zhang, W | 1 |
| Standl, E | 1 |
| Tibaldi, JM | 1 |
| Mullard, A | 1 |
| Dimmitt, SB; Doggrell, SA | 1 |
| Davis, TM | 2 |
| Athyros, VG; Elisaf, MS; Filippatos, TD | 1 |
| Gallwitz, B; Nitschmann, S | 1 |
| Clifton, P | 1 |
| Dicembrini, I; Mannucci, E | 1 |
| Burciu, C; Koska, J; Reaven, P; Sands, M | 1 |
| Hirshberg, B; Katz, A | 1 |
| Bhamidipati, RK; Gilibili, RR; Mullangi, R; Srinivas, NR | 1 |
| Špinar, J; Špinarová, L; Vítovec, J | 1 |
| Castelli, MP; Davidson, C; De Luca, MA; Di Chiara, G; Kellett, K; Loi, B; Martorelli, M; Miliano, C; Porcu, A; Schifano, F; Stair, JL | 1 |
| Baker, WL; White, WB | 1 |
| Warren, RB; Yiu, ZZ | 1 |
| Jermendy, G | 1 |
| Järbe, TU; LeMay, BJ; Makriyannis, A; Thakur, GA | 1 |
| Cahn, A; Raz, I; Schernthaner, G | 1 |
| Bingham-Gardiner, P; Bolodeoku, J; Hassan, SW; Lee, S; Scowcroft, A; Spencer, W; Tebboth, A | 1 |
| Borea, PA; Canazza, I; De Luca, MA; Di Rosa, F; Fantinati, A; Gregori, A; Margiani, G; Marti, M; Ossato, A; Rimondo, C; Serpelloni, G; Trapella, C; Varani, K; Vincenzi, F | 1 |
| Raz, I; Tkáč, I | 1 |
| Hernández, C; Simó, R | 1 |
| Arao, T; Hajime, M; Kuno, F; Kurozumi, A; Mine, S; Miyazaki, M; Mori, H; Narisawa, M; Okada, Y; Sonoda, S; Sugai, K; Tanaka, K; Tanaka, Y; Torimoto, K | 1 |
| Mannucci, E; Monami, M | 1 |
| Kimura, K; Takayanagi, R; Uchida, T; Yamada, Y | 2 |
| Lingvay, I | 1 |
| Burlaka, YB; Grin, NV; Khilchevskyi, OM; Sukhoveev, OV; Verevka, SV | 1 |
| Kaneko, M; Narukawa, M | 1 |
| Ettrup, A; Farde, L; Finnema, SJ; Halldin, C; Knudsen, GM; Martinsson, S; Stepanov, V; Takano, A; Yang, KC | 1 |
| Abeni, D; Collina, MC; Di Zenzo, G; Didona, B; Fania, L; Mazzanti, C; Pagnanelli, G; Provini, A; Salemme, A | 1 |
| Cardwell, LA; Cline, A; Feldman, SR | 1 |
| Alexander, GC; Baksh, SN; McAdams-DeMarco, M; Segal, JB | 1 |
| Westhovens, R | 1 |
| Aykara, I; Diller, M; Frommer, K; Hasseli, R; Hülser, ML; Müller-Ladner, U; Neumann, E; Rehart, S | 1 |
| Feng, Q; Guo, M; Qiu, Q; Tan, X | 1 |
| Ferrante, M; Sabino, J | 1 |
| Cheng, CY; Chiang, CP; Chien, WC; Chung, CH; Hung, CT; Liu, JS; Wang, WM | 1 |
| Dicembrini, I; Mannucci, E; Monami, M; Montereggi, C; Nreu, B | 1 |
| Georgiou, S; Plachouri, KM | 1 |
| Lee, YH; Song, GG | 1 |
| Gyu Song, G; Ho Lee, Y | 1 |
| Morinobu, A | 1 |
| Emori, T; Fujii, Y; Hashimoto, M; Higashi, Y; Ito, H; Kasahara, M; Narumiya, S; Sugahara, S | 1 |
| Aletaha, D; Baraliakos, X; Boehncke, WH; de Wit, M; Dörner, T; Dougados, M; Emery, P; Fleischmann, RM; Geissler, K; Isaacs, JD; Kerschbaumer, A; Kremer, J; Lee, EB; Maksymowych, WP; McInnes, I; Nash, P; Pope, JE; Smolen, JS; Stoffer-Marx, M; Takeuchi, T; Tam, LS; Tanaka, Y; Trauner, M; van den Bosch, F; van der Heijde, D; Voshaar, M; Westhovens, R; Winthrop, KL; Xavier, R | 1 |
| Hardman, TC; Hucke, O; Klein, T; Nar, H; Schnapp, G | 1 |
| Karkara, BB; Kumar, A; Panda, G | 1 |
| Cai, ZJ; Chen, T; Li, N; Lin, WQ; Liu, MB; Zheng, B | 1 |
| Kim, JW; Kim, SY | 1 |
| Guo, L; Jiang, X; Wang, L; Zhang, L | 1 |
41 review(s) available for adamantane and piperidines
| Article | Year |
|---|---|
Diabetes: assessing the pipeline.
Topics: Adamantane; Alkanesulfonates; Amyloid; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exenatide; Glycine; Humans; Hypoglycemic Agents; Indoles; Islet Amyloid Polypeptide; Maleimides; Nitriles; Oxazoles; Peptides; Phenylpropionates; Piperidines; PPAR alpha; PPAR gamma; Protein Kinase C; Pyrazoles; Pyrrolidines; Receptor, Cannabinoid, CB1; Receptors, Glucagon; Rimonabant; Venoms; Vildagliptin | 2006 |
[New concepts in the treatment of type 2 diabetes].
Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Nitriles; Peptides; Piperidines; Pyrazines; Pyrazoles; Pyrrolidines; Rimonabant; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV.
Topics: Adamantane; Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Nitriles; Piperidines; Pyrrolidines; Uracil; Vildagliptin | 2008 |
DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy.
Topics: Adamantane; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Pioglitazone; Piperidines; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Uracil | 2009 |
The physiologic role of incretin hormones: clinical applications.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Incretins; Piperidines; Pyrazines; Sitagliptin Phosphate; Triazoles; Uracil | 2010 |
Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Liraglutide; Nitriles; Obesity; Patient Compliance; Peptides; Piperidines; Precision Medicine; Primary Health Care; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin | 2010 |
Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2010 |
DPP-4 inhibitors: what may be the clinical differentiators?
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Gastric Emptying; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Intestinal Mucosa; Linagliptin; Neurons; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2010 |
Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Topics: Adamantane; Age Factors; Aged; Aging; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Male; Middle Aged; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Vildagliptin | 2011 |
Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.
Topics: Adamantane; Biomarkers; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Models, Biological; Nitriles; Piperidines; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2012 |
DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Topics: Adamantane; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin; Weight Gain | 2012 |
An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glucagon-Like Peptide 1; Humans; Linagliptin; Male; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2012 |
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2013 |
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2013 |
Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Peptides; Piperidines; Purines; Pyrazines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Weight Loss | 2014 |
Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment.
Topics: Adamantane; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Glycated Hemoglobin; Humans; Piperidines; Renal Insufficiency; Risk Factors; Treatment Outcome; Uracil | 2014 |
The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Piperidones; Purines; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Thiazolidines; Triazoles; Uracil; Vildagliptin | 2014 |
Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Hospitalization; Humans; Nitriles; Piperidines; Pyrrolidines; Sitagliptin Phosphate; Uracil; Vildagliptin | 2014 |
Risk of myocardial infarction in trials with Dipeptidyl Peptidase-4 inhibitors: Is duration of study a real issue?
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Incidence; Myocardial Infarction; Patient Outcome Assessment; Patient Selection; Piperidines; Research Design; Time Factors; Uracil | 2015 |
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
Topics: Adamantane; Animals; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Incretins; Piperidines; Protective Factors; Risk Assessment; Risk Factors; Treatment Outcome; Uracil | 2015 |
Insights from cardiovascular outcome trials with novel antidiabetes agents: what have we learned? An industry perspective.
Topics: Adamantane; Cardiovascular System; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Piperidines; Sitagliptin Phosphate; Treatment Outcome; Uracil | 2015 |
[The TECOS, EXAMINE and SAVOR studies--how do they differ and what are their outcomes?].
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Piperidines; Sitagliptin Phosphate; Uracil | 2015 |
Cardiovascular Effects of Incretin-Based Therapies.
Topics: Adamantane; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Heart Failure; Humans; Hypoglycemic Agents; Incretins; Piperidines; Sitagliptin Phosphate; Uracil | 2016 |
Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.
Topics: Adamantane; Adenosine; Adenosine A3 Receptor Antagonists; Administration, Oral; Arthritis, Psoriatic; Azetidines; Biological Factors; Biological Therapy; Clinical Trials as Topic; Humans; Isonicotinic Acids; Janus Kinases; Niacinamide; Phosphodiesterase 4 Inhibitors; Piperidines; Protein Kinase Inhibitors; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Receptors, Lysosphingolipid; rho-Associated Kinases; Sulfonamides; Thalidomide; Thiazoles | 2016 |
[Cardiovascular safety of incretin-based antidiabetic treatment - results of completed clinical trials].
Topics: Adamantane; Cardiovascular System; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Heart Failure; Humans; Hypoglycemic Agents; Incretins; Peptides; Piperidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Time Factors; Uracil | 2016 |
Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes.
Topics: Acute Disease; Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Incidence; Pancreatitis; Piperidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Uracil | 2017 |
Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Meta-Analysis as Topic; Peptides; Piperidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Uracil | 2017 |
SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Metformin; Piperidines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Uracil | 2017 |
Advances in treating psoriasis in the elderly with small molecule inhibitors.
Topics: Adamantane; Azetidines; Clinical Trials as Topic; Humans; Niacinamide; Nitriles; Phosphodiesterase 4 Inhibitors; Piperidines; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Severity of Illness Index; Small Molecule Libraries; Sulfonamides; Thalidomide | 2017 |
Clinical efficacy of new JAK inhibitors under development. Just more of the same?
Topics: Adamantane; Arthritis, Rheumatoid; Azetidines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase 1; Janus Kinase 3; Janus Kinase Inhibitors; Niacinamide; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Triazoles; Valine | 2019 |
JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis.
Topics: Adamantane; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cell Proliferation; Humans; Janus Kinase 3; Janus Kinase Inhibitors; Methotrexate; Niacinamide; Piperidines; Pyrimidines; Pyrroles | 2019 |
Efficacy of JAK inhibitors in Ulcerative Colitis.
Topics: Adamantane; Colitis, Ulcerative; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Niacinamide; Piperidines; Pyrimidines; Treatment Outcome | 2020 |
Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Incidence; Neoplasms; Piperidines; Randomized Controlled Trials as Topic; Risk Factors; Sitagliptin Phosphate; Uracil; Vildagliptin | 2020 |
JAK inhibitors in chronic plaque psoriasis: What is known so far.
Topics: Adamantane; Azetidines; Humans; Janus Kinase Inhibitors; Janus Kinases; Niacinamide; Nitriles; Piperidines; Prospective Studies; Psoriasis; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Triazoles | 2020 |
Comparison of the efficacy and safety of tofacitinib and peficitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Drug Therapy, Combination; Humans; Network Meta-Analysis; Niacinamide; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome | 2020 |
Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Bayes Theorem; Heterocyclic Compounds, 3-Ring; Humans; Niacinamide; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides; Triazoles | 2020 |
JAK inhibitors for the treatment of rheumatoid arthritis.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Benzofurans; Cardiovascular Diseases; Herpes Zoster; Humans; Janus Kinases; Molecular Targeted Therapy; Neutropenia; Niacinamide; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Venous Thromboembolism | 2020 |
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
Topics: Adamantane; Advisory Committees; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Azetidines; Cytokines; Drug Therapy, Combination; Europe; Heterocyclic Compounds, 3-Ring; Humans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Niacinamide; Piperidines; Psoriasis; Purines; Pyrazoles; Pyridines; Pyrimidines; Rheumatology; Spondylarthropathies; Spondylitis, Ankylosing; Sulfonamides; Triazoles | 2021 |
Novel candidates in the clinical development pipeline for TB drug development and their synthetic approaches.
Topics: Adamantane; Animals; Antitubercular Agents; DNA Gyrase; Drug Development; Enzyme Inhibitors; Humans; Isonicotinic Acids; Mycobacterium tuberculosis; Oxazolidinones; Piperidines; Pyrroles; Structure-Activity Relationship; Tuberculosis; Tuberculosis, Multidrug-Resistant; Uridine | 2021 |
The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment.
Topics: Adamantane; Colitis; Colitis, Ulcerative; Crohn Disease; Heterocyclic Compounds, 3-Ring; Humans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Janus Kinases; Niacinamide; Piperidines; Pyridines; Pyrimidines; Pyrroles; Triazoles | 2021 |
The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis.
Topics: Adamantane; Azetidines; Heterocyclic Compounds; Humans; Immunosuppressive Agents; Janus Kinase Inhibitors; Janus Kinases; Network Meta-Analysis; Niacinamide; Piperidines; Protein Kinase Inhibitors; Psoriasis; Purines; Pyrazoles; Pyrimidines; Sulfonamides; Treatment Outcome | 2022 |
3 trial(s) available for adamantane and piperidines
| Article | Year |
|---|---|
Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.
Topics: Adamantane; Biomarkers; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Models, Biological; Nitriles; Piperidines; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2012 |
Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer's disease.
Topics: Adamantane; Aged; Alzheimer Disease; Donepezil; Double-Blind Method; Female; Humans; Indans; Male; Neuropsychological Tests; Nootropic Agents; Piperazines; Piperidines; Treatment Outcome | 2014 |
Comparative analysis of the effects of alogliptin and vildagliptin on glucose metabolism in type 2 diabetes mellitus.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose; Glycated Hemoglobin; Humans; Male; Middle Aged; Nitriles; Piperidines; Pyrrolidines; Treatment Outcome; Uracil; Vildagliptin | 2017 |
64 other study(ies) available for adamantane and piperidines
| Article | Year |
|---|---|
Animal models for an integrated approach to the pharmacologic control of atherosclerosis.
Topics: Adamantane; Aniline Compounds; Animals; Arteriosclerosis; Clofibrate; Coturnix; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Haplorhini; Humans; Hypolipidemic Agents; Macaca fascicularis; Male; Mitotane; Piperidines; Rats; Terminology as Topic | 1979 |
Biological activity of a hypobetalipoproteinemic agent.
Topics: Adamantane; Animals; Bridged-Ring Compounds; Cholesterol; Cholesterol, Dietary; Cholic Acids; Columbidae; Diet, Atherogenic; Dose-Response Relationship, Drug; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins, LDL; Male; Mice; Piperidines; Quail; Rats | 1976 |
Response to the hypobetalipoproteinemic agent adamantyloxyphenyl piperidine in hyperlipemic rats.
Topics: Adamantane; Animals; Bridged-Ring Compounds; Cholesterol; Hypercholesterolemia; Hyperlipidemias; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Liver; Male; Organ Size; Organ Specificity; Piperidines; Rats | 1977 |
Muscarinic receptor subtypes in human and guinea pig lung.
Topics: Adamantane; Adult; Aged; Animals; Atropine; Guinea Pigs; Humans; In Vitro Techniques; Lung; Middle Aged; Parasympatholytics; Piperidines; Pirenzepine; Protease Inhibitors; Quinuclidinyl Benzilate; Receptors, Muscarinic; Species Specificity | 1989 |
LY353433, a potent, orally effective, long-acting 5-HT(4) receptor antagonist: comparison to cisapride and RS23597-190.
Topics: Adamantane; Administration, Oral; Aminobenzoates; Animals; Cisapride; Esophagus; Female; In Vitro Techniques; Indazoles; Male; Muscle Relaxation; para-Aminobenzoates; Piperidines; Rats; Rats, Inbred F344; Rats, Sprague-Dawley; Rats, Wistar; Serotonin Antagonists | 1996 |
Comparison of responses to T-kinin and bradykinin in the mesenteric vascular bed of the cat.
Topics: Adamantane; Analysis of Variance; Animals; Bradykinin; Bradykinin Receptor Antagonists; Cats; Cimetidine; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Female; Histamine Antagonists; Male; Meclofenamic Acid; Mesentery; Morpholines; NG-Nitroarginine Methyl Ester; Piperidines; Potassium Channels; Pyrilamine | 1997 |
Characterization of binding sites of a new neurotensin receptor antagonist, [3H]SR 142948A, in the rat brain.
Topics: Adamantane; Animals; Autoradiography; Binding Sites; Brain; Imidazoles; Male; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, Neurotensin; Tritium | 1998 |
Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; Animals; Autoradiography; Binding Sites; Carrier Proteins; Caudate Nucleus; Denervation; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Down-Regulation; Imidazoles; In Situ Hybridization; Macaca fascicularis; Membrane Glycoproteins; Membrane Transport Proteins; Neostriatum; Nerve Tissue Proteins; Neurotensin; Piperidines; Putamen; Receptors, Dopamine; Receptors, Neurotensin; RNA, Messenger; Substantia Nigra | 1999 |
Neurotensin depolarizes cholinergic and a subset of non-cholinergic septal/diagonal band neurons by stimulating neurotensin-1 receptors.
Topics: Action Potentials; Adamantane; Animals; Dose-Response Relationship, Drug; Female; Guinea Pigs; Histamine H1 Antagonists; Imidazoles; In Vitro Techniques; Male; Membrane Potentials; Neurons; Neurotensin; Patch-Clamp Techniques; Piperidines; Prosencephalon; Receptors, Neurotensin; Tetrodotoxin | 1999 |
Motor effects of (-)-OSU6162 in primates with unilateral 6-hydroxydopamine lesions.
Topics: Adamantane; Animals; Apomorphine; Benzazepines; Benzopyrans; Callithrix; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Piperidines; Quinpirole; Rotation | 2000 |
Neurotensin regulates intracellular calcium in ventral tegmental area astrocytes: evidence for the involvement of multiple receptors.
Topics: Adamantane; Animals; Animals, Newborn; Astrocytes; Calcium; Cells, Cultured; Estrenes; Gadolinium; Imidazoles; Neurotensin; Peptide Fragments; Piperidines; Pyrrolidinones; Rats; Receptors, Neurotensin; Thapsigargin; Type C Phospholipases; Ventral Tegmental Area | 2000 |
The effect of neighboring 1- and 2-adamantyl group substitution on the conformations and stereodynamics of N-methylpiperidine. Dynamic NMR spectroscopy and molecular mechanics calculations.
Topics: Adamantane; Magnetic Resonance Spectroscopy; Molecular Conformation; Piperidines; Protons; Stereoisomerism | 2001 |
Synthesis and antioxidant activity evaluation of novel antiparkinsonian agents, aminoadamantane derivatives of nitroxyl free radical.
Topics: Adamantane; Amantadine; Animals; Antioxidants; Antiparkinson Agents; Brain; Dopamine; Female; Free Radicals; Immunohistochemistry; Molecular Structure; Nitrogen Oxides; Parkinsonian Disorders; Piperidines; Rats; Rats, Inbred BUF; Reactive Oxygen Species; Spectrophotometry; Tyrosine 3-Monooxygenase | 2003 |
Pruritus-associated response mediated by cutaneous histamine H3 receptors.
Topics: Adamantane; Amidines; Animals; Female; Histamine Agonists; Histamine H2 Antagonists; Imidazoles; Mast Cells; Methylhistamines; Mice; Mice, Inbred ICR; Mice, Mutant Strains; Piperidines; Pruritus; Receptors, Histamine H3; Skin | 2004 |
(-)-Adamantyl-delta8-tetrahydrocannabinol (AM-411), a selective cannabinoid CB1 receptor agonist: effects on open-field behaviors and antagonism by SR-141716 in rats.
Topics: Adamantane; Animals; Cannabinoid Receptor Antagonists; Cannabinoids; Dronabinol; Drug Interactions; Exploratory Behavior; Male; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Rimonabant | 2004 |
The novel cannabinoid agonist AM 411 produces a biphasic effect on accuracy in a visual target detection task in rats.
Topics: Adamantane; Animals; Dose-Response Relationship, Drug; Dronabinol; Mice; Muscarinic Antagonists; Pattern Recognition, Visual; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Scopolamine; Task Performance and Analysis | 2005 |
Synthesis, conformational characteristics and anti-influenza virus A activity of some 2-adamantylsubstituted azacycles.
Topics: Adamantane; Animals; Antiviral Agents; Cell Line; HIV; Humans; Influenza A Virus, H3N2 Subtype; Magnetic Resonance Spectroscopy; Molecular Conformation; Molecular Structure; Piperidines; Pyrrolidines; Viruses | 2006 |
In vitro biological efficiency of tenocyclidine-TCP and its adamantane derivative TAMORF.
Topics: Adamantane; Cell Survival; Cholinesterase Inhibitors; Cholinesterase Reactivators; Chromosome Aberrations; Comet Assay; Erythrocytes; Gamma Rays; Humans; In Vitro Techniques; Lethal Dose 50; Leukocytes; Lymphocytes; Morpholines; Mutagens; Phencyclidine; Piperidines; Radiation-Protective Agents; Soman; Structure-Activity Relationship; Thiophenes; Trypan Blue | 2006 |
Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention.
Topics: Adamantane; Cells, Cultured; Fibroblasts; Gaucher Disease; Glucosylceramidase; Humans; Imino Pyranoses; Lysosomes; Models, Molecular; Mutation; Piperidines; Sorbitol; Stereoisomerism; Structure-Activity Relationship | 2007 |
Dipeptidyl peptidase 8/9-like activity in human leukocytes.
Topics: Adamantane; Antibodies, Monoclonal; Dipeptidases; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Enzyme Activation; Humans; Indoles; Isoleucine; Leukocytes; Molecular Conformation; Nitriles; Organophosphonates; Piperidines; Proline; Protease Inhibitors; Pyrrolidines; Stereoisomerism; Structure-Activity Relationship; Vildagliptin | 2007 |
Heterogeneity of thylakoid membranes studied by EPR spin probe.
Topics: Adamantane; Algorithms; Chlorophyll; Cyclic N-Oxides; Electron Spin Resonance Spectroscopy; Entropy; Free Radicals; Photosystem I Protein Complex; Piperidines; Spin Labels; Thylakoids | 2007 |
The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats.
Topics: Adamantane; Analysis of Variance; Animals; Behavior, Animal; Conditioning, Operant; Cyclic AMP; Dose-Response Relationship, Drug; Dronabinol; Drug Interactions; Eating; Male; Motor Activity; Nausea; Piperidines; Protein Binding; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Reinforcement, Psychology | 2008 |
Design and synthesis of 1,2-annulated adamantane piperidines with anti-influenza virus activity.
Topics: Adamantane; Animals; Antiviral Agents; Dogs; Humans; Influenza A Virus, H3N2 Subtype; Magnetic Resonance Spectroscopy; Molecular Structure; Piperidines; Rimantadine; Structure-Activity Relationship | 2009 |
Neurotensin inhibition of GABAergic transmission via mGluR-induced endocannabinoid signalling in rat periaqueductal grey.
Topics: Adamantane; Animals; Cannabinoid Receptor Modulators; Endocannabinoids; Excitatory Amino Acid Antagonists; Female; gamma-Aminobutyric Acid; Imidazoles; In Vitro Techniques; Inhibitory Postsynaptic Potentials; Male; Miniature Postsynaptic Potentials; Neural Inhibition; Neurons; Neurotensin; Pain; Periaqueductal Gray; Piperidines; Presynaptic Terminals; Pyrazoles; Pyridines; Quinolines; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Receptors, Neurotensin; Synaptic Transmission; Tetrodotoxin; Time Factors | 2009 |
Qualitative GC-MS assessment of TCP and TAMORF elimination in rats.
Topics: Adamantane; Animals; Gas Chromatography-Mass Spectrometry; Male; Morpholines; Organophosphate Poisoning; Phencyclidine; Piperidines; Rats; Rats, Wistar; Thiophenes | 2010 |
1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain.
Topics: Adamantane; Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Epoxide Hydrolases; Humans; Male; Mice; Morphine; Pain; Piperidines; Rats; Rats, Sprague-Dawley; Solubility; Structure-Activity Relationship; Urea | 2010 |
An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
Topics: Adamantane; Allylamine; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Investigational New Drug Application; Liraglutide; Nitriles; Peptides; Piperidines; Practice Guidelines as Topic; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Time Factors; Triazoles; United States; United States Food and Drug Administration; Uracil; Venoms; Vildagliptin | 2011 |
Identification of SQ609 as a lead compound from a library of dipiperidines.
Topics: Adamantane; Animals; Antitubercular Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Macrophages; Mice; Mice, Inbred C3H; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Piperidines; Small Molecule Libraries; Structure-Activity Relationship; Weight Loss | 2011 |
[Therapeutic use and adverse events of incretin-related drugs].
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin | 2012 |
Diuretic effects of cannabinoids.
Topics: Adamantane; Animals; Arachidonic Acids; Benzoxazines; Body Temperature; Cannabinoid Receptor Antagonists; Cannabinoids; Cannabinol; Confidence Intervals; Diuresis; Diuretics; Dose-Response Relationship, Drug; Dronabinol; Female; Male; Morpholines; Naphthalenes; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Water | 2013 |
New adamantane phenylalkylamines with σ-receptor binding affinity and anticancer activity, associated with putative antagonism of neuropathic pain.
Topics: Adamantane; Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Proliferation; Female; Humans; Male; Mice; Mice, SCID; Molecular Structure; Neuralgia; Ovarian Neoplasms; Pancreatic Neoplasms; Piperidines; Prostatic Neoplasms; Protein Binding; Receptors, sigma; Structure-Activity Relationship; Tumor Cells, Cultured | 2012 |
Effect of hypoglycemic agents on ischemic preconditioning in patients with type 2 diabetes and symptomatic coronary artery disease.
Topics: Adamantane; Aged; Carbamates; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Ischemic Preconditioning; Male; Middle Aged; Nitriles; Piperidines; Prospective Studies; Pyrrolidines; Vildagliptin | 2013 |
Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect?
Topics: Adamantane; Aged; Angioedema; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Substitution; Humans; Male; Nitriles; Piperidines; Pyrrolidines; Uracil; Vildagliptin | 2013 |
A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site.
Topics: Adamantane; Catalytic Domain; Crystallography, X-Ray; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Multiprotein Complexes; Nitriles; Oligopeptides; Piperidines; Protein Binding; Protein Interaction Mapping; Pyrazines; Pyrazoles; Pyrrolidines; Serine; Sitagliptin Phosphate; Structure-Activity Relationship; Thiazolidines; Triazoles; Uracil; Vildagliptin; X-Ray Diffraction | 2013 |
Kainate-induced calcium overload of cortical neurons in vitro: Dependence on expression of AMPAR GluA2-subunit and down-regulation by subnanomolar ouabain.
Topics: Adamantane; Animals; Calcium; Calcium Signaling; Cells, Cultured; Cerebral Cortex; Disease Models, Animal; Down-Regulation; Enzyme Inhibitors; Female; In Vitro Techniques; Kainic Acid; Nerve Degeneration; Neurons; Ouabain; Patch-Clamp Techniques; Piperidines; Pregnancy; Rats; Rats, Wistar; Receptors, AMPA | 2013 |
New oral hypoglycaemics fail to show cardiovascular benefits.
Topics: Adamantane; Cardiovascular Diseases; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Piperidines; Randomized Controlled Trials as Topic; Treatment Failure; Uracil | 2013 |
Diabetes: Cardiovascular safety of 'gliptin' therapy.
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Piperidines; Uracil | 2013 |
Pharmacotherapy: Cardiovascular safety of antihyperglycaemic drugs in patients with type 2 diabetes mellitus.
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Piperidines; Uracil | 2013 |
New drugs improve glycemic control in type 2 diabetes, but improving heart health remains elusive.
Topics: Adamantane; Blood Glucose; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Drug Approval; Humans; Hypoglycemic Agents; Piperidines; Uracil | 2013 |
Pharmacoeconomic analysis of DPP-4 inhibitors.
Topics: Adamantane; Clinical Trials as Topic; Cohort Studies; Cost-Benefit Analysis; Costs and Cost Analysis; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nitriles; Piperidines; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2013 |
Saxagliptin, alogliptin, and cardiovascular outcomes.
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Piperidines; Uracil | 2014 |
Outcome results renew debate about diabetes drug development.
Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Drug Approval; Humans; Hypoglycemic Agents; Piperidines; Treatment Outcome; Uracil | 2013 |
Gliptins - do they increase cardiovascular risk or benefit?
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Piperidines; Uracil | 2014 |
Dipeptidyl peptidase-4 inhibitors and cardiovascular safety.
Topics: Adamantane; Blood Glucose; Cardiovascular Diseases; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Piperidines; Uracil | 2014 |
[New antihyperglycemic drugs. Examination of cardiovascular outcomes with alogliptin versus standard of care (EXAMINE) and saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Piperidines; Uracil | 2014 |
Retrospective and Prospective Human Intravenous and Oral Pharmacokinetic Projection of Dipeptidyl peptidase-IV Inhibitors Using Simple Allometric Principles - Case Studies of ABT-279, ABT-341, Alogliptin, Carmegliptin, Sitagliptin and Vildagliptin.
Topics: Adamantane; Administration, Intravenous; Administration, Oral; Animals; Biphenyl Compounds; Dipeptidyl-Peptidase IV Inhibitors; Dogs; Haplorhini; Humans; Nitriles; Piperidines; Prospective Studies; Pyridines; Pyrrolidines; Quinolizines; Rats; Retrospective Studies; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2015 |
Native CB1 receptor affinity, intrinsic activity and accumbens shell dopamine stimulant properties of third generation SPICE/K2 cannabinoids: BB-22, 5F-PB-22, 5F-AKB-48 and STS-135.
Topics: Adamantane; Animals; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Central Nervous System Stimulants; Dopamine Agents; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Indazoles; Indoles; Male; Mice, Inbred C57BL; Mice, Knockout; Molecular Structure; Naphthalenes; Nucleus Accumbens; Piperidines; Prefrontal Cortex; Pyrazoles; Quinolines; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1 | 2016 |
A high efficacy cannabinergic ligand (AM4054) used as a discriminative stimulus: Generalization to other adamantyl analogs and Δ(9)-THC in rats.
Topics: Adamantane; Animals; Cannabinol; Discrimination Learning; Dronabinol; Generalization, Psychological; Male; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant | 2016 |
Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Humans; Hypoglycemic Agents; Piperidines; Risk Factors; Sitagliptin Phosphate; Uracil | 2016 |
Demographic and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Initiating Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Study of UK General Practice.
Topics: Adamantane; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; General Practice; Humans; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Nitriles; Piperidines; Pyrrolidines; Retrospective Studies; Sitagliptin Phosphate; Uracil; Vildagliptin | 2016 |
Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on "tetrad", sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies.
Topics: Adamantane; Aggression; Animals; Behavior, Animal; Binding, Competitive; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Cannabis; Catalepsy; Dopamine; Dronabinol; Humans; In Vitro Techniques; Indazoles; Indoles; Male; Mice; Motor Activity; Naphthalenes; Nucleus Accumbens; Pain Threshold; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Reflex, Abnormal; Seizures | 2016 |
New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.
Topics: Adamantane; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Peptides; Piperidines; Risk; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Uracil | 2016 |
Evaluation of drug efficacy of DPP-4 inhibitors based on theoretical analysis with pharmacokinetics and pharmacodynamics.
Topics: Adamantane; Algorithms; Area Under Curve; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nitriles; Piperidines; Pyrrolidines; Treatment Outcome; Uracil; Vildagliptin | 2017 |
EPR spectroscopy studies of changes in erythrocyte membranes in patients with laryngeal cancer.
Topics: Adamantane; Aged; Carcinoma, Squamous Cell; Electron Spin Resonance Spectroscopy; Erythrocyte Membrane; Humans; Laryngeal Neoplasms; Lipid Bilayers; Male; Membrane Fluidity; Membrane Lipids; Membrane Proteins; Middle Aged; Molecular Probes; Molecular Structure; Neoplasm Staging; Piperidines; Time Factors; Viscosity | 2017 |
Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Hospitalization; Humans; Piperidines; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk; Sitagliptin Phosphate; Uracil | 2017 |
Fenfluramine Reduces [11C]Cimbi-36 Binding to the 5-HT2A Receptor in the Nonhuman Primate Brain.
Topics: Adamantane; Aminoquinolines; Animals; Benzylamines; Brain; Brain Mapping; Dose-Response Relationship, Drug; Female; Fenfluramine; Fluorobenzenes; Macaca mulatta; Magnetic Resonance Imaging; Phenethylamines; Piperidines; Positron-Emission Tomography; Protein Binding; Purinergic P2X Receptor Antagonists; Receptor, Serotonin, 5-HT2A; Serotonin Agents | 2017 |
Detection and characterization of IgG, IgE, and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors.
Topics: Adamantane; Aged; Aged, 80 and over; Autoantibodies; Autoantigens; Collagen Type XVII; Dipeptidyl-Peptidase IV Inhibitors; Epitopes; Female; Humans; Immunoglobulin A; Immunoglobulin E; Immunoglobulin G; Linagliptin; Male; Membrane Glycoproteins; Middle Aged; Nitriles; Non-Fibrillar Collagens; Pemphigoid, Bullous; Piperidines; Pyrrolidines; Sitagliptin Phosphate; Uracil; Vildagliptin | 2018 |
Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy.
Topics: Adamantane; Algorithms; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Monitoring; Exenatide; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Ligands; Liraglutide; Models, Molecular; Molecular Targeted Therapy; Nitriles; Peptides; Piperidines; Pyrrolidines; Reproducibility of Results; Sitagliptin Phosphate; Uracil; Venoms; Vildagliptin | 2018 |
Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.
Topics: Adamantane; Administration, Oral; Adverse Drug Reaction Reporting Systems; Aged; Bayes Theorem; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Heart Failure; Humans; Linagliptin; Male; Middle Aged; Piperidines; Practice Guidelines as Topic; Sitagliptin Phosphate; United States; United States Food and Drug Administration; Uracil | 2018 |
Targeting Activated Synovial Fibroblasts in Rheumatoid Arthritis by Peficitinib.
Topics: Adamantane; Arthritis, Rheumatoid; Azetidines; Cell Proliferation; Chemokine CCL2; Fibroblasts; Humans; Interleukin-6; Janus Kinase Inhibitors; Niacinamide; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Synovial Membrane | 2019 |
Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, population-based, cohort study in Taiwan.
Topics: Adamantane; Adult; Age Factors; Aged; Case-Control Studies; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Incidence; Linagliptin; Male; Middle Aged; Pemphigoid, Bullous; Piperidines; Risk Factors; Sitagliptin Phosphate; Taiwan; Uracil; Vildagliptin; Young Adult | 2020 |
Role of JAK-STAT signaling in the pathogenic behavior of fibroblast-like synoviocytes in rheumatoid arthritis: Effect of the novel JAK inhibitor peficitinib.
Topics: Adamantane; Apoptosis; Arthritis, Rheumatoid; Azetidines; Cells, Cultured; Cytokines; Humans; Janus Kinase Inhibitors; Janus Kinases; Niacinamide; Phosphorylation; Piperidines; Purines; Pyrazoles; Pyrimidines; Signal Transduction; STAT3 Transcription Factor; Sulfonamides; Synoviocytes | 2020 |
Action of Dipeptidyl Peptidase-4 Inhibitors on SARS-CoV-2 Main Protease.
Topics: Adamantane; Antiviral Agents; Coronavirus 3C Proteases; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Repositioning; Enzyme Assays; Heterocyclic Compounds; Linagliptin; Piperidines; SARS-CoV-2; Sitagliptin Phosphate; Uracil | 2021 |
Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China.
Topics: Adamantane; China; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Resistance; Drug Therapy, Combination; Humans; Linagliptin; Metformin; Middle Aged; Piperidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Uracil; Vildagliptin | 2021 |